Myriad Genetics, Pharma Mar Explore PGx Strategy for DNA-Damaging Synthetic Alkaloid PM1183 | GenomeWeb

Originally published July 30.

Myriad Genetics will use its BRACAnalysis test to pick out best responders to PM1183, a new type of DNA-damaging agent that drug developer Pharma Mar is studying as a potential treatment for advanced breast cancer.

Under this latest companion diagnostics agreement involving its flagship BRACAnalysis test, Myriad will assess the BRCA status of metastatic breast cancer patients enrolled in a Phase II study investigating Pharma Mar's PM1183.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.